Researchers have developed an AI-based platform that can design custom proteins to enhance T cell responses against cancer cells, significantly reducing the time needed for treatment development. This innovative method allows for tailored immunotherapy by creating specific molecular keys that guide immune cells to attack tumors while minimizing damage to healthy tissue. The approach has shown promise in laboratory tests and aims to enter clinical trials within five years.